INBUILD
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Patient / Population Intervention / Exposure Comparison Outcome
In 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.
N
663
Design
Multicentre RCT
Endpoint
Annual rate of FVC decline
Relevance
2
Result-80.8 vs -187.8 mL/year (difference 107 mL; p<0.001); effect consistent across UIP and non-UIP HRCT pattern.
Flaherty KR, et al. N Engl J Med. 2019;381(18):1718-1727. 10.1056/NEJMoa1908681
Discussion & critique
Broadened nintedanib's indication beyond IPF to any progressive fibrosing ILD.